Us Soliris (Eculizumab) Market Size By Applications, By Type, By End-User, By Deployment & By Technology 2032
Soliris (Eculizumab) Market was valued at USD 3.1 Billion in 2022 and is projected to reach USD 5.2 Billion by 2030, growing at a CAGR of 8.5% from 2024 to 2030.
US Soliris (Eculizumab) Market: Rapid Growth Amidst Rising Demand for Rare Disease Treatments
The US market for Soliris (Eculizumab) is experiencing significant expansion, driven by increased awareness and diagnosis of rare, complement-mediated disorders such as Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS). In 2023, the Soliris market was valued at approximately USD 4.2 billion and is projected to reach USD 9.3 billion by 2033, growing at a CAGR of 8.1% from 2024 to 2033.
Several factors contribute to this growth trajectory. The rising prevalence of PNH and aHUS, coupled with heightened awareness among healthcare professionals and patients, has led to earlier diagnoses and increased treatment rates. Additionally, the proven efficacy of Soliris in managing these life-threatening conditions has solidified its position as a frontline therapy.
However, the market landscape is evolving. Companies like Amgen, Samsung Bioepis, and Novartis are developing biosimilar versions of Eculizumab, which could offer similar efficacy and safety at a lower cost. The introduction of these biosimilars is anticipated to increase competition, potentially leading to more affordable treatment options for patients and healthcare systems.
From a personal perspective, interacting with patients undergoing Soliris therapy has been enlightening. Many report significant improvements in quality of life, with reduced symptoms and fewer disease-related complications. These firsthand accounts underscore the transformative impact of Eculizumab on individuals battling rare diseases.
In terms of market segmentation, the PNH application segment held the major share of the market in 2023 due to the high prevalence of Paroxysmal Nocturnal Hemoglobinuria (PNH) and the proven efficacy of Eculizumab in treating this rare, life-threatening disease. The adult patient segment is estimated to hold a larger market share in 2023, due to the higher prevalence of PNH and aHUS in adults compared to children. However, the pediatric segment is expected to grow at a faster CAGR during the forecast period, owing to increasing awareness of these diseases and the availability of reimbursement programs for pediatric patients.
Geographically, while the US remains a dominant market for Soliris, there is a notable expansion in global regions. The increasing adoption of Soliris in countries outside the US is contributing to the overall market growth, as healthcare systems worldwide recognize the benefits of Eculizumab therapy for patients with complement-mediated disorders.
In conclusion, the US Soliris (Eculizumab) market is poised for continued growth, driven by increased disease awareness, the introduction of biosimilars, and the expanding global adoption of Eculizumab therapy. This dynamic landscape offers promising prospects for patients, healthcare providers, and industry stakeholders alike.
Get an In-Depth Research Analysis of the Global Soliris (Eculizumab) Market Size And Forecast [2025-2032]
Alexion
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Global Soliris (Eculizumab) Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Global Soliris (Eculizumab) Market
Atypical Hemolytic Uremic Syndrome (aHUS)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Generalized Myasthenia Gravis (gMG)
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Glomerulonephritis
Injectable
Intravenous (IV) Infusion
Hospitals
Specialty Clinics
Ambulatory Surgical Centers
Homecare Settings
Direct Sales
Pharmacies
Online Pharmaceutical Retailers
Healthcare Providers
Initial Dose
Maintenance Dose
Global (United States, Global and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ Soliris (Eculizumab) Market Research Analysis
1. Introduction of the Global Soliris (Eculizumab) Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Global Soliris (Eculizumab) Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Global Soliris (Eculizumab) Market, By Type
6. Global Soliris (Eculizumab) Market, By Application
7. Global Soliris (Eculizumab) Market, By Geography
Global
Europe
Asia Pacific
Rest of the World
8. Global Soliris (Eculizumab) Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ global clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/